Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.64 |
| ▸ | CDK9 | P50750 | 5/20 | 0.64 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.64 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.64 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.64 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.59 |
| ▸ | CDC42BPB | Q9Y5S2 | 11/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.59 |
| ▸ | CDC42BPA | Q5VT25 | 7/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | PRKACA | P17612 | 2/20 | 0.49 |
| ▸ | FRK | P42685 | 2/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.49 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993889 | 0.82 | CDK2 (0.64) | CDK2CDK9CDK5CCNT1CCNA2 | |
| SCHEMBL2988182 | 0.82 | CCNT1 (0.68) | CDK2CDK9CDK5CCNT1CCNA2 | |
| SCHEMBL2996408 | 0.82 | CCNT1 (0.64) | CDK2CDK9CDK5CCNT1CCNA2 | |
| SCHEMBL24672106 | 0.80 | CDK2 (0.61) | CDK2CDK9CDK5CCNT1CCNA2 | |
| SCHEMBL20744107 | 0.80 | CDK9 (0.61) | CDK2CDK9CDK5CCNT1CCNA2 | |
| SCHEMBL30668694 | 0.80 | CDK9 (0.61) | CDK2CDK9CDK5CCNT1CCNA2 | |
| SCHEMBL2993897 | 0.79 | CCNT1 (0.65) | CDK2CDK9CDK5CCNT1CCNA2 | |
| SCHEMBL2997834 | 0.78 | CCNT1 (1.00) | CDK2CDK9CDK5CCNT1CCNA2 | |
| SCHEMBL2992172 | 0.78 | CDK5 (0.60) | CDK2CDK9CDK5CCNT1CCNA2 | |
| SCHEMBL2994119 | 0.78 | CCNT1 (0.64) | CDK2CDK9CDK5CCNT1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| EP-2125803-B1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2013-04-10 | — | — | EP | disclosed |
| US-20100184790-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184790-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF | BAD, PPOX, CASP3 | CDK2 127/4885CDK9 527/4885CDK5 15/4885 |
| US-11447505-B1 | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer | PDXK, CCNK, CDC42BPB | CDK2 71/4885CDK9 76/4885CDK5 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.